ABSTRACT: Background. Few human papillomavirus (HPV)(þ) head and neck squamous cell carcinoma (HNSCC) cell lines exist. We established University of Michigan-squamous cell carcinoma-104 (UM-SCC-104), a new HPV(þ) HNSCC cell line from a recurrent oral cavity tumor, and characterized it for the presence of cancer stem cells (CSCs).
The establishment of cell lines from primary tumors is essential to head and neck squamous cell cancer (HNSCC) research. While many cell lines have been successfully established in the last 30 years, [1] [2] [3] there are few that have been derived from cancers naturally infected with high-risk human papillomavirus (HR-HPV) in the head and neck. In recent years, it has become clear that the overwhelming majority of oropharyngeal tumors are now associated with HR-HPV and there is strong evidence that the presence of HR-HPV in the tumor is an independent prognostic factor in overall survival for patients diagnosed with HNSCC. 4, 5 However, not all patients with HPV(þ) tumors respond well to therapy and the reasons for failure in some cases are not known. 6, 7 The availability of HR-HPV-containing cell lines enhances our ability to study the role that HPV plays in HNSCC development and response or resistance to therapy.
The selective pressure on cells in the formation of an immortal cell line has been discussed previously. 2, 8, 9 There are limitations in using cell line behavior to reflect that of the original tumor because it is speculative that cell lines truly reflect the behavior of primary tumors. However, despite this, it is well documented that cell lines remain the fundamental tools for preclinical investigations in the most efficient and cost-effective way. Other preclinical models, such as the use of xenografts, are equally valuable and important to investigate cancer cell behavior; however, cell lines avoid high cost and ethical issues that inevitably arise when using animal models.
Our group and others have studied biomarker expression in HNSCC in HPV(þ) and HPV(À) tumors, with HPV and p16
INK4a emerging as biomarkers associated with improved prognosis in oropharyngeal cancer. 7, [10] [11] [12] Epidermal growth factor receptor (EGFR), p53, and Bcl-xL are also relevant markers that modify the prognostic effect of HPV and may help guide the development of targeted therapy in HNSCC. 6, 10 CDKN2a encodes the cyclin-dependent kinase inhibitor p16 INK4a , which is almost always overexpressed in HPV(þ) oropharyngeal tumors, and is often lost or silenced in HPV(À) head and neck tumors 13 with only rare examples of p16
INK4a positive/HPV(À) tumors. 14 Overexpression of p16 INK4a , like HPV, is an independent positive prognostic indicator for HNSCC. 15 E-cadherin and nuclear b-catenin may also play a role in tumor progression in HPV-related tumors, and studies of these biomarkers may help to elucidate differences in tumor biology between HPV(þ) and HPV(À) tumors. 16 In our characterization, we chose to look at biomarkers that have been studied before and implicated in HNSCC prognosis.
Cancer stem cells (CSCs) have been isolated in HNSCC using the cellular expression of aldehyde dehydrogenase (ALDH activity). [17] [18] [19] The ALDHþ CSC subpopulation (also called the tumor initiating cell population) is highly tumorigenic, can self-renew, and has the capacity to recreate the initial tumor heterogeneity. Development of therapeutic strategies targeting CSC pathways necessitates identification of this important subpopulation in primary tumors and cell lines. 20 In effect, distinguishing CSCs in new and existing cell lines is paramount to developing novel approaches in targeting these cancer-initiating cells. In this article, we describe the development and characterization of a new HPV(þ) HNSCC cell line that contains a tumorigenic CSC population.
MATERIALS AND METHODS
Approvals for use of the animal model were obtained through the University of Michigan Committee for the Humane Care and Use of Animals. The University of Michigan's Guide for the Care and Use of Laboratory Animals was followed.
Establishment of the cell line
Written informed consent was obtained from the patient for the study of his tissue and medical records after review and approval of the study and the consent form by the Medical School Institutional Review Board. Surgically resected tumor tissue was carefully selected for culture by the surgeon (D. B. C.), immediately transported to the laboratory, and was washed extensively in Earle's balanced salt solution containing penicillin, streptomycin, and amphotericin B. The tissue was then minced, placed in culture flasks, and covered with complete Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, L-glutamine, penicillin, and streptomycin. 2, 3 The tumor was heavily infected with yeast, therefore, amphotericin B (20 lg/mL) was also added to the medium and frequent washing was used to remove as much of the yeast as possible with each medium change. Eventually, sterile cultures were obtained and propagated. Trypsin with 0.125% EDTA was used for partial trypsinization to aid in fibroblast removal. When sufficient outgrowth of cells was observed, cells were detached using warm trypsin and plated into new culture flasks. The cells have been carried through multiple passages. Supernatants were tested for mycoplasma using Myco Alert Mycoplasma Testing Kit (Lonza, Rockland, ME).
Analysis of genetic loci
DNA was extracted from University of Michigan-squamous cell carcinoma (UM-SCC-104) tumor cells and from fibroblasts separated from the UM-SCC-104 culture during cell line establishment using a modified Promega Wizard protocol (Promega, Madison, WI). Briefly, the genotyping procedure is as follows: cell pellets are re-suspended in Nuclei Lysis Solution at 55 C. Proteins are precipitated, vortexed, then chilled on ice and separated by centrifugation at 13K revolutions per minute. DNA in the lysis supernatant is precipitated with isopropanol, diluted to 0.10 ng/ lL and submitted to the University of Michigan Sequencing Core for analysis with the Profiler Plus PCR Amplification Kit (Applied Biosystems, Foster City, CA). Ten loci are analyzed: D3S1358, vWA, FGA, D8S1179, D21S11, D18S51, D5S818, D13S317, and D7S820, and the amelogenin locus for identifying the presence of the X and Y chromosomes. Polymerase chain reaction (PCR) products are analyzed using the Applied Biosciences 3730 DNA sequencer and allele sizes are detected fluorescently.
Flow cytometry
ALDH activity was detected using the Aldefluor kit (Stem Cell Technologies, Vancouver, British Columbia, Canada). Briefly, cells from the primary tumor were brought to single cell suspension in Aldefluor assay buffer, and incubated with ALDH substrate (Bodipy aminoacetaldehyde (BAAA), 5 lmol/L per 1 Â 10 6 cells) for 45 minutes at 37 C. Concurrently, diethylaminobenzaldehyde (DEAB 50 mmol/L) was added to a separate sample also containing BAAA for an ALDH-inhibited control. Samples were washed and resuspended in Aldefluor assay buffer. We used 4 0 , 6-diamidino-2-phenylindole (BD Pharmingen, San Diego CA) as a cell viability indicator. Fluorescenceactivated cell sorting gates were established using the inhibited control (DEAB) and the cell viability sample diamidino-2-phenylindole.
In vivo tumor production from cancer stem cells
ALDH
High and ALDH Low fractions from UM-SCC-104 were collected into separate tubes and 5000 cells from each fraction were suspended in 100 lL of Dulbecco's modified Eagle's medium with 100 lL of Matrigel (BD Biosciences, San Jose, CA) for in vivo injections. The resulting 200 lL cell suspensions were injected subcutaneously into opposite flanks of a nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse (strain #001303, Jackson Laboratories, Bar Harbor, ME). Tumor grown from the ALDH High inoculation was allowed to persist until the growth reached 1 cm in size (10 Immunohistochemistry UM-SCC-104 cells were cultured on chamber slides until 50% confluent and then were fixed and permeabilized with 4% paraformaldehyde and 0.1% Triton-x for 15 minutes for each step (Sigma, St. Louis, MO). Fixed slides were kept in phosphate-buffered saline at 4 C until staining. Tissue slides from the surgical specimen and from the primary tumor murine xenograft were deparaffinized, rehydrated, and peroxidase-quenched (Dako Cytomation, Glostrup, Denmark). All slides except for 1 were incubated in Antigen Retrieval Solution (Dako Cytomation) for 40 minutes in a 92 C water bath with a buffer change midway and allowed to cool to room temperature for 20 minutes. For EGFR, the antigen retrieval step was performed with pepsin incubation for 10 minutes at 37 C. Horse serum was used for blocking (30 minutes at room temperature). Sections were stained with primary antibodies: monoclonal mouse anti-EGFR/31G7 (Invitrogen, Camirillo, CA), monoclonal mouse anti-Bcl-2/124 (Dako Cytomation), monoclonal mouse anti-p53/DO1 (Calbiochem, Darmstadt, Germany), monoclonal rabbit anticyclin D1/SP4, and monoclonal mouse anti-Rb/51B7 (Neomarkers, Fremont, CA). Primary antibodies were added and allowed to incubate overnight at 4 C. Staining for p16
INK4a was performed per protocol supplied by the kit (CINtec p16
INK4a Histology Kit; mtm Laboratories, Westborough, MA). Slides were washed and incubated with corresponding biotinylated secondary antibodies (Vector Laboratories, Burlingame, CA) at 1:200 dilution for 30 minutes. The slides were washed and incubated in a solution of coupled avidin/horseradish peroxidase (ABC Kit; Vector Laboratories), allowing linkage to the secondary antibodies via avidin-biotin binding. After washing, a DAB Peroxidase Substrate Kit (Vector Laboratories) was used to detect primary antibody binding. After a final washing step in tap water, the specimens were dehydrated and mounted. The stained slides were interpreted by a pathologist (J. B. McHugh).
Human papillomavirus detection and human papillomavirus type identification
DNA was isolated from UM-SCC-104 and from the primary tumor tissue using DNeasy Blood and Tissue Kit (Qiagen). The presence and type of high risk HPV DNA was detected using the Mass Array technique developed by Dr. David Kurnit modified as described herein. 21 Multiplex PCR amplification of the E6 region of 15 discrete high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, 66, 68, and 73), as well as a human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) control (Table 1A for a list of primers) was run to saturation followed by shrimp alkaline phosphatase quenching. Amplification reactions included a competitor oligonucleotide identical to each natural amplicon except for a single nucleotide difference. Shrimp alkaline phosphatase removes p53
Abbreviations: HPV, human papillomavirus; F, forward primer; R, reverse primer; E, extension primer; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RT-PCR, reverse transcriptasepolymerase chain reaction.
phosphate from residual free dNTPs in the reaction mixture to prevent their incorporation in the next step, a single base extension reaction, which uses terminal bases. This multiplex single base extension reaction uses probes (primer E, Table 1A ) that identify unique sequences in the E6 region of each type, extending at the single base difference between wild-type and competitor HPV. The extension PCR product from each HPV type and its competitor can then be distinguished by mass (40 or 80 Dalton difference between wild type and competitor) when analyzed on the matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometer 21, 22 ( Figure 1 ). In situ hybridization was carried out in the pathology laboratory on formalin-fixed paraffin-embedded sections of the resected tumor using the INFORM HPVIII ISH assay (Ventana, Tucson, AZ), which consists of a FIGURE 1. PCR-MassARRAY using MALDI-TOF mass spectroscopy to detect and type human papillomavirus. Diagram depicting three-step process of HPV detection by competitive multiplex PCR amplification using 15 hrHPV type-specific primer pairs for HPV E6 & hGAPDH.
Amplification of HPVE6 occurs in episomal and/or integrated viral DNA as well as each of the synthetic competitors. PCR, polymerase chain reaction; hrHPV, high-risk human papillomavirus; HPV, human papillomavirus; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MALDI, matrix assisted laser desorption ionization; TOF, time of flight. RNA extraction, reverse transcription polymerase chain reaction, gene sequencing
RNA from UM-SCC-104 was isolated by phenol-chloroform extraction with TRIzol (Invitrogen). cDNA was synthesized using Reverse Transcription System Kit (Promega) in accord with the manufacturer's protocol, and detection of p53, E6, and E7 was performed using primers listed in Table 1B . The HPV-16-containing CaSki cervical carcinoma cell line and the HPV-16(þ) UM-SCC-47 oropharyngeal carcinoma cell line developed in our laboratory 23 were used as positive controls and the known HPV(À) cell line UM-SCC-38 was used as a negative control for E6 and E7 (amplicon sizes 477 base pairs and 400 base pairs, respectively; Table 1B for primers). The complete p53 cDNA was sequenced with 3 overlapping primer sets: amplicon 1 (652 base pairs), amplicon 2 (719 base pairs), and amplicon 3 (534 base pairs; Table 1C for primers). PCR products were submitted to the University of Michigan Sequencing Core for target gene sequencing. cDNA sequencing covers the entire p53 transcript including all exons and is the preferred method of sequencing as it can identify splicing variants as well as point mutations within the coding regions.
RESULTS

Case report
UM-SCC-104 was derived from a 56-year-old man with a recurrent floor of mouth squamous cell carcinoma. He was initially treated at a different hospital in 2008 with wide local excision for a posterior sublingual tumor that was described as moderately to poorly differentiated squamous cell carcinoma. Four months later, he had a second wide local excision of a recurrent tumor of the floor of mouth and, because of continuing suspicion of persistent disease in the floor of mouth-mandibular alveolus, he was treated with chemoradiation (no details were available on the agents used, the doses, or duration of treatment). After the completion of radiation, the 
University of michigan-squamous cell carcinoma-104
Explanted tissue produced outgrowths of cells approximately on day 7 of culture ( Figure 2A ). At this point, multiple culture flasks were found to contain yeast, and amphotericin B was added to the culture medium. Cultures were fed and rinsed with amphotericin B-containing medium until cultures no longer contained the contaminant. Differential trypsinization successfully removed fibroblast overgrowth leaving behind the epithelial cells. By day 21, the first passage of tumor cells to new flasks could be accomplished. The tumor cells were frozen at multiple low passages and were considered established as a cell line after the passage 20 milestone. UM-SCC-104 has a doubling time of 48 hours. Separate colony formation is typical of UM-SCC-104, and colonies will not become over-confluent ( Figure 2B ). This mirrors the histologic appearance of the grape-like clusters of tumor cells in the patient's anterior floor of mouth lesion tumor tissue, which was determined to be a moderately to poorly differentiated invasive squamous cell carcinoma ( Figure 2C ). This histologic appearance was recapitulated in subcutaneous tumors produced in the mouse after inoculation of ALDH High tumor cells ( Figure 2D ).
University of michigan-squamous cell carcinoma-104 genotype
The genotype of UM-SCC-104 is unique among the genotypes of our entire collection of cell lines. 23 As shown in Table 2 , the genotype of the UM-SCC-104 cell line and the fibroblasts that grew out from the normal stroma are nearly identical, except that the tumor cells show loss of 1 allele at each of 2 loci, D3S1358 and FGA.
Cancer stem cell derived xenograft UM-SCC-104 cells sorted for ALDH expression revealed a 2.3% ALDH High population ( Figure 3A and 3B). Cells selected for high and low ALDH activity were inoculated subcutaneously into opposite sides of NOD/ SCID mice. Tumor growth resulted from the ALDH High injection after 6 weeks ( Figure 3C and 3D) whereas no growth was observed from the ALDH Low injection even after 10 weeks of observation at which time the tumor from the ALDH High inoculation was harvested. Xenograft tissue morphology consisted of thick cords and clusters of poorly differentiated squamous cells similar to those in the tumor tissue taken from the patient (compare Figure 2C and 2D ). Figure 4 shows a comparison of biomarker expression in the patient's tumor tissue, the murine xenograft, and the UM-SCC-104 cell line. Sections of the resected tumor tissue had weak expression of Rb and Bcl-2. In the xenograft tumor, Rb was expressed only in mitotic cells, but in the cell line all nuclei strongly expressed Rb. Bcl-2 also was not detected in the xenograft but is expressed in nuclei and cytoplasm of many cells in the UM-SCC-104 cell line, with the strongest expression in mitotic nuclei. The p53 overexpression is present in a subset of the nuclei of the patient's tumor, in a lower proportion of the xenograft cells, and in a high proportion of nuclei in the cell line. Similarly, cyclin D expression is found in focal areas in the patient tumor and the xenograft, but is strongly expressed in nearly all of the cells in the cell line. All cells within the patient tumor, xenograft, and the cell line strongly express diffuse nuclear and cytoplasmic p16 INK4a . Similarly, all cells in the tumor, the xenograft, and the cell line exhibit strong and diffuse membranous staining for EGFR.
Head and neck cancer biomarkers
Human papillomavirus and p53 status
In situ hybridization on the patient's tumor demonstrated scattered cells with large punctate nuclear signals consistent with the presence of integrated HPV DNA (Figure 5A) . In comparison, an adjacent section cut from the same block at the same time exhibited strong p16 staining in all tumor cells ( Figure 5B ). The presence of HPV in DNA from the patient's tumor and the UM-SCC-104 cell line was confirmed and identified as HPV-16 by PCRMassARRAY with MALDI-TOF mass spectroscopy (Figure 6) . Expression of strong HPV-16 E6 and E7 oncogenes were demonstrated by reverse transcriptase-polymerase chain reaction (RT-PCR) in UM-SCC-104 and in the HPV-16 positive controls, Caski and UM-SCC-47 cell lines (Figure 7) . The HPV-16 E6 primer set amplifies both . [23] [24] [25] [26] [27] Review of the literature indicates that all of the donors of HPV(þ) cell lines were smokers (Table  3 ). There are other HPVþ HNSCC cell lines, UPCI-152 established from a recurrence in the donor of UPCI-90 and UPCI 154, established from a different patient at the University of Pittsburgh (personal communication, Susanne Gollin 41, 42 ), that are available for studying HPV oncogenesis in head and neck cancer. Herein, we present a new HPV(þ) cell line derived from a persistent (third recurrence) oral cavity tumor. The tumor and the cell line both contain high-risk HPV-16 with HPV persisting in the tumor cells in culture. This cell line, UM-SCC-104, is a new in vitro and in vivo resource for studying convergent viral and carcinogen-related pathways of carcinogenesis because the patient was a heavy smoker and used alcohol for many years. Unlike many HPV(þ) tumors, this tumor recurred after surgery and failed to respond to chemoradiation, and thus, provides a model for use in SCC-104) . Sections of the primary tumor tissue, the CSC-derived tumor and the cell line all exhibited strong and diffuse nuclear and cytoplasmic staining for p16INK4a. Cell membrane staining was also strong and diffuse for EGFR in all three tumor cell samples. Approximately 10% of the resected tumor cells over-expressed p53, while staining was negative for RB, Bcl-2 and cyclin D. There was 10% focal staining of RB and cyclin D and 5% focal staining for p53, while no expression of Bcl-2 was seen on mouse tissue sections. UM-SCC-104 cultured on chamber slides uniformly over-expressed p16INK4a, EGFR and Rb. Focal staining of cyclin D1 (20%), Bcl-2 (20%) and p53 (30%) was present in the cell line. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary. preclinical studies to identify potential targets for novel therapies. Tumors like UM-SCC-104 that represent the aggressive nonresponsive tumors are those for which new therapies must be developed if we are to offer the afflicted individuals more effective tumor control.
UM-SCC-104 -AN HPV16 POSITIVE ORAL CAVITY CELL
HPV(þ) tumors of the head and neck are now viewed as a separate and biologically distinct entity from HNSCC linked to smoking and alcohol consumption. [28] [29] [30] The presence of HPV is a powerful independent predictor of response to therapy and overall survival in patients with HNSCC, 10,11 furthermore, patients with HPV(þ) tumors are significantly less likely to be tobacco users. 10, 30, 31 Hafkamp et al, 7 studying a group of patients with tonsillar cancer that were mostly smokers (84%), observed that there was a marked difference in survival rate between smokers and nonsmokers with HPV-associated tumors. Maxwell et al 6 reported that of the oropharyngeal cancer population who were HPV(þ), only about one third were never smokers, and two thirds of patients who were HPV(þ) were either current or former smokers. Furthermore, never smokers had a 5-fold lower risk of cancer progression (recurrence, distant metastasis, or second primary cancer of the head and neck) than that of current smokers with HPV(þ) tumors. This observation was subsequently expanded upon in a large cooperative trial. 4 Thus, a positive tobacco history in patients with HPV(þ) tumors may represent a distinct group of head and neck cancers when all HNSCC are divided by etiologic factors (ie, group 1: HPV(À) smokers; group 2: HPV(þ) never smokers; group 3: and HPV(þ) ever smokers). UM-SCC-104 belongs to the group 3 demographic which have a higher risk of recurrence than HPV(þ) tumors from never smokers 6 supporting the need for representative cell lines for further studies.
The creation of an HPV(þ) cell line in HNSCC is a rare event even though the majority of oropharyngeal tumors are now HPV(þ). For successful attachment and subsequent in vitro propagation, it is thought that the tumor cells must have acquired traits compatible with survival and immortality in the unnatural environment of in vitro cultivation. 2, 8 HPV(þ) head and neck cancer cell lines are generally from patients with aggressive tumors that fail to respond to initial therapy. From what has been published about the existing HPV(þ) cell lines and from the history of UM-SCC-47, patients from which they were derived were smokers 23, 27, 32, 33 (Table 3) . Tumors from HPV(þ) smokers may more readily accumulate the genetic differences necessary for in vitro survival, which may account for the aggressive tumor behavior seen in this demographic.
UM-SCC-104 was derived from a patient who was a welder and had an extensive smoking (20 pack/year) and consistent moderate alcohol history. Thus, this patient had the usual etiologic factors for head and neck cancer, but also had a tumor that was HPV(þ). It was initially thought that his smoking and alcohol use and the floor of mouth primary site indicated a typical chemical carcinogen-induced tumor. However, upon verification of his HPV(þ) tumor status, it became clear that there was a more complex process involved in tumorigenesis. One large retrospective study stratified risk factors by tumor site and found the strongest risk for an oral cavity tumor site was alcohol, while smoking was most strongly associated with laryngeal cancer and HPV-16 with pharyngeal cancer. 30 Had our patient tested negative for HPV, his tumor would have been attributed to carcinogens related to tobacco and alcohol usage and possibly environmental hazards from his occupation. Our patient's high-risk HPV status most likely provided an additive and possibly synergistic effect with his other risk factors contributing to the development of the cancer. 34 UM-SCC-104 is a cell line that will be an important resource to begin to investigate how these combined risk factors contribute to the formation of such a therapeutically nonresponsive tumor.
The floor of mouth is an unusual site for HPV-related tumors. We confirmed the presence of HPV in the surgical specimen and in UM-SCC-104 using multiple methods: the patient's recurrent tumor demonstrated integrated HPV DNA by in situ hybridization; the tumor and the cell line exhibited uniform overexpression of p16
INK4a
(immunohistochemical analysis); E6 and E7 expression (RT-PCR) and HPV type 16 (multiplex PCR/MALDI-TOF mass spectroscopy) were also observed in the tumor and the UM-SCC-104 cell line. There is currently no universal method for HPV detection in head and neck cancer, although numerous techniques and algorithms have been proposed, 35 and our data are unequivocal in demonstrating that this floor of mouth/oral cavity tumor is HPV-16 positive. Although the original site was described as the posterior floor of the mouth and designated as an oral cavity tumor, HPV(þ) tumors of the oral cavity are rare and it cannot be excluded that the tumor originated in a never discovered small base of tongue tumor but presented through local extension into the floor of the mouth.
We characterized the primary tumor and UM-SCC-104 for additional HNSCC biomarkers that have been linked to both tumor behavior and response to therapy. The tumor and the cell line overexpress EGFR. We previously reported the phenotype HPV(þ)/EGFR High to be associated with poorer survival after chemotherapy and radiation than HPV(þ)/EGFR Low tumors. 10 Cyclin D1 is also overexpressed in a proportion of UM-SCC-104 cells. High cyclin D1 expression is linked to poor prognosis in head and neck cancer 36 and in a clinical trial of organsparing therapy for laryngeal cancer, cyclin D1 overexpression was a single variable that was clearly indicative of poor survival (Bradford et al, Triologic Thesis, unpublished data). Reduced expression of cyclin D1 in HPV(þ) head and neck tumors has been reported when compared to HPV(À) tumors induced by smoking and alcohol. 12 This makes sense because cyclin D1 and HPV E7 oncoprotein both target Rb. The E7 oncoprotein sequesters Rb allowing E2F-mediated transcription of the genes involved in entry into the cell cycle to proceed unopposed whereas cyclin D1 activates cyclin-dependent kinase that phosphorylates Rb achieving the same effect as E7, making both mechanisms unnecessary in the same tumor cell. We previously reported that smoking is associated with increased EGFR expression in oropharyngeal cancers, and that increased EGFR expression strongly reduced the beneficial effect on survival associated with HPV. 10 The increased expression of cyclin D1 in UM-SCC-104 is consistent with the patient's smoking history as well as increased EGFR expression, because EGFR signaling activates STAT3 which in turn upregulates cyclin D1 expression 37 providing an alternative mechanism of Rb activation through cyclin dependent kinase activation. However, in UM-SCC-104 this activation may be countered to some degree by the E2F-driven high expression of p16 INK4a , which acts as an inhibitor of cyclin-dependent kinases.
Curiously, the proportion of biomarker-positive cells differed somewhat in the cell line and the tumor. Rb, p53, Bcl-2, and cyclin D1 all showed higher proportions of positive cells in the cell line compared to the original tumor specimen. Because cells with these characteristics may have greater growth potential, it is logical that the cell line might therefore be enriched in these types of cells particularly under conditions of proliferation in vitro. There have been conflicting data on p53 expression in HPV(þ) HNSCC tumor cells. Some studies have observed high expression of nuclear p53 in some HPV-containing tumors with wild-type p53 14 and other studies demonstrating low p53 expression. 38 The mechanism of overexpression of wild-type p53 in the presence of the virus is unknown. The expectation in HPV(þ) cells is that the E6 protein of highrisk HPV types recruits E6-associated protein (E6AP), a cellular ubiquitin ligase to the E6-p53-E6AP complex, allowing ubiquitination of p53, which marks it for exportation from the nucleus and into the proteasome for degradation. Why some HPV(þ) tumors show overexpressed nuclear p53 is not fully understood. In UM-SCC-104 cells, the in situ hybridization signal for HPV was not uniform throughput the tumor suggesting that the viral genome may have been rearranged or might be in the process of being lost. We also noted in these cells a higher expression of an alternate splice form of HPV E6 called E6* than of the full-length E6 transcript. It is unknown whether the E6* is less effective in causing p53 degradation than the fulllength E6 protein, but it is interesting to speculate that this might be the case and thus provide an explanation for high p53 expression in these HPV transformed tumor cells.
In accordance with the cancer stem cell theory, a small subpopulation of high ALDH-expressing cells 39 from the UM-SCC-104 cell line was capable of forming a new tumor in an immunocompromised mouse, whereas ALDHnegative cells were unable to form a tumor. Xenotransplantation is considered the gold standard for identification of CSCs. It allows demonstration of essential CSC characteristics including the ability for the cells to selfrenew and differentiate into various cell progeny. 40 The tumor derived from the CSCs displayed the primary tumor phenotypic heterogeneity indicating that this selected cell population has inherent stem-like functions that other cells do not. Accordingly, we observed congruency in biomarker expression in the mouse tumor of EGFR, p16 INK4a , cyclin D, and p53 compared to the primary section.
CONCLUSIONS
The existence of HPV(þ) cell lines from head and neck tumors provides opportunities to study HPV-related carcinogenesis in head and neck cancer. UM-SCC-104 is a new HPV(þ) cell line that also contains a small and functionally important cancer stem cell population. This cell line will be a valuable resource to further determine relevant molecular pathways in both HPV and CSC carcinogenesis.
